Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer

M Bandini, M Marchioni, F Preisser, E Zaffuto, Z Tian, D Tilki, F Montorsi, SF Shariat, F Saad, A Briganti, PI Karakiewicz

Research output: Contribution to journalArticle

Abstract

Purpose: No prospective data examined the effect of radical prostatectomy (RP) vs. external beam radiotherapy (EBRT) in locally advanced prostate cancer (PCa). We aimed to compare survival outcomes of RP and EBRT in patients harboring cT3N0-1 PCa. Methods: Within the SEER database (2004–2014), we identified 5500 cT3N0-1 PCa patients. Cumulative incidence plots and competing-risks regression models (CRRs) tested cancer-specific mortality (CSM) and other cause of mortality (OCM) according to treatment type. The multivariable relationship between baseline prostate-specific antigen (PSA) values and 10-year CSM after either RP or EBRT was graphically depicted using the LOESS smoothing method. Sensitivity analyses were performed in cT3N0-only patients, after OCM propensity score matching, and through landmark analyses. Results: Ten-year CSM and OCM rates were significantly higher after EBRT (15.8 and 28.2%) than RP (8.1 and 10.4%) (all p < 0.0001). In multivariable CRRs, RP yielded lower CSM [hazard ratio (HR): 0.64] than EBRT. Significantly lower 10-year CSM rate was recorded after RP vs. EBRT through the entire range of baseline PSA values. The same results were recorded in cT3N0 subgroup, as well as after OCM propensity score matching. Finally, landmark analyses at 6, 12, 24, and 36 months rejected the effect of favorable survival bias after RP. Conclusions: CSM was significantly lower after RP than EBRT in cT3N0-1 PCa. A lower CSM was recorded throughout the entire range of baseline PSA and even in cT3N0 subgroup, as well as after OCM propensity score matching and landmark analyses. © 2018 Springer-Verlag GmbH Germany, part of Springer Nature
Original languageEnglish
Pages (from-to)1399-1407
Number of pages9
JournalWorld Journal of Urology
Volume36
Issue number9
DOIs
Publication statusPublished - 2018

Fingerprint

Prostatectomy
Prostatic Neoplasms
Radiotherapy
Survival
Mortality
Propensity Score
Prostate-Specific Antigen
Neoplasms
Germany
Databases

Cite this

Bandini, M., Marchioni, M., Preisser, F., Zaffuto, E., Tian, Z., Tilki, D., ... Karakiewicz, PI. (2018). Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer. World Journal of Urology, 36(9), 1399-1407. https://doi.org/10.1007/s00345-018-2310-y

Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer. / Bandini, M; Marchioni, M; Preisser, F; Zaffuto, E; Tian, Z; Tilki, D; Montorsi, F; Shariat, SF; Saad, F; Briganti, A; Karakiewicz, PI.

In: World Journal of Urology, Vol. 36, No. 9, 2018, p. 1399-1407.

Research output: Contribution to journalArticle

Bandini, M, Marchioni, M, Preisser, F, Zaffuto, E, Tian, Z, Tilki, D, Montorsi, F, Shariat, SF, Saad, F, Briganti, A & Karakiewicz, PI 2018, 'Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer', World Journal of Urology, vol. 36, no. 9, pp. 1399-1407. https://doi.org/10.1007/s00345-018-2310-y
Bandini, M ; Marchioni, M ; Preisser, F ; Zaffuto, E ; Tian, Z ; Tilki, D ; Montorsi, F ; Shariat, SF ; Saad, F ; Briganti, A ; Karakiewicz, PI. / Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer. In: World Journal of Urology. 2018 ; Vol. 36, No. 9. pp. 1399-1407.
@article{d88868ac1cfc4989850556ca45045bf6,
title = "Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer",
abstract = "Purpose: No prospective data examined the effect of radical prostatectomy (RP) vs. external beam radiotherapy (EBRT) in locally advanced prostate cancer (PCa). We aimed to compare survival outcomes of RP and EBRT in patients harboring cT3N0-1 PCa. Methods: Within the SEER database (2004–2014), we identified 5500 cT3N0-1 PCa patients. Cumulative incidence plots and competing-risks regression models (CRRs) tested cancer-specific mortality (CSM) and other cause of mortality (OCM) according to treatment type. The multivariable relationship between baseline prostate-specific antigen (PSA) values and 10-year CSM after either RP or EBRT was graphically depicted using the LOESS smoothing method. Sensitivity analyses were performed in cT3N0-only patients, after OCM propensity score matching, and through landmark analyses. Results: Ten-year CSM and OCM rates were significantly higher after EBRT (15.8 and 28.2{\%}) than RP (8.1 and 10.4{\%}) (all p < 0.0001). In multivariable CRRs, RP yielded lower CSM [hazard ratio (HR): 0.64] than EBRT. Significantly lower 10-year CSM rate was recorded after RP vs. EBRT through the entire range of baseline PSA values. The same results were recorded in cT3N0 subgroup, as well as after OCM propensity score matching. Finally, landmark analyses at 6, 12, 24, and 36 months rejected the effect of favorable survival bias after RP. Conclusions: CSM was significantly lower after RP than EBRT in cT3N0-1 PCa. A lower CSM was recorded throughout the entire range of baseline PSA and even in cT3N0 subgroup, as well as after OCM propensity score matching and landmark analyses. {\circledC} 2018 Springer-Verlag GmbH Germany, part of Springer Nature",
author = "M Bandini and M Marchioni and F Preisser and E Zaffuto and Z Tian and D Tilki and F Montorsi and SF Shariat and F Saad and A Briganti and PI Karakiewicz",
year = "2018",
doi = "10.1007/s00345-018-2310-y",
language = "English",
volume = "36",
pages = "1399--1407",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer

AU - Bandini, M

AU - Marchioni, M

AU - Preisser, F

AU - Zaffuto, E

AU - Tian, Z

AU - Tilki, D

AU - Montorsi, F

AU - Shariat, SF

AU - Saad, F

AU - Briganti, A

AU - Karakiewicz, PI

PY - 2018

Y1 - 2018

N2 - Purpose: No prospective data examined the effect of radical prostatectomy (RP) vs. external beam radiotherapy (EBRT) in locally advanced prostate cancer (PCa). We aimed to compare survival outcomes of RP and EBRT in patients harboring cT3N0-1 PCa. Methods: Within the SEER database (2004–2014), we identified 5500 cT3N0-1 PCa patients. Cumulative incidence plots and competing-risks regression models (CRRs) tested cancer-specific mortality (CSM) and other cause of mortality (OCM) according to treatment type. The multivariable relationship between baseline prostate-specific antigen (PSA) values and 10-year CSM after either RP or EBRT was graphically depicted using the LOESS smoothing method. Sensitivity analyses were performed in cT3N0-only patients, after OCM propensity score matching, and through landmark analyses. Results: Ten-year CSM and OCM rates were significantly higher after EBRT (15.8 and 28.2%) than RP (8.1 and 10.4%) (all p < 0.0001). In multivariable CRRs, RP yielded lower CSM [hazard ratio (HR): 0.64] than EBRT. Significantly lower 10-year CSM rate was recorded after RP vs. EBRT through the entire range of baseline PSA values. The same results were recorded in cT3N0 subgroup, as well as after OCM propensity score matching. Finally, landmark analyses at 6, 12, 24, and 36 months rejected the effect of favorable survival bias after RP. Conclusions: CSM was significantly lower after RP than EBRT in cT3N0-1 PCa. A lower CSM was recorded throughout the entire range of baseline PSA and even in cT3N0 subgroup, as well as after OCM propensity score matching and landmark analyses. © 2018 Springer-Verlag GmbH Germany, part of Springer Nature

AB - Purpose: No prospective data examined the effect of radical prostatectomy (RP) vs. external beam radiotherapy (EBRT) in locally advanced prostate cancer (PCa). We aimed to compare survival outcomes of RP and EBRT in patients harboring cT3N0-1 PCa. Methods: Within the SEER database (2004–2014), we identified 5500 cT3N0-1 PCa patients. Cumulative incidence plots and competing-risks regression models (CRRs) tested cancer-specific mortality (CSM) and other cause of mortality (OCM) according to treatment type. The multivariable relationship between baseline prostate-specific antigen (PSA) values and 10-year CSM after either RP or EBRT was graphically depicted using the LOESS smoothing method. Sensitivity analyses were performed in cT3N0-only patients, after OCM propensity score matching, and through landmark analyses. Results: Ten-year CSM and OCM rates were significantly higher after EBRT (15.8 and 28.2%) than RP (8.1 and 10.4%) (all p < 0.0001). In multivariable CRRs, RP yielded lower CSM [hazard ratio (HR): 0.64] than EBRT. Significantly lower 10-year CSM rate was recorded after RP vs. EBRT through the entire range of baseline PSA values. The same results were recorded in cT3N0 subgroup, as well as after OCM propensity score matching. Finally, landmark analyses at 6, 12, 24, and 36 months rejected the effect of favorable survival bias after RP. Conclusions: CSM was significantly lower after RP than EBRT in cT3N0-1 PCa. A lower CSM was recorded throughout the entire range of baseline PSA and even in cT3N0 subgroup, as well as after OCM propensity score matching and landmark analyses. © 2018 Springer-Verlag GmbH Germany, part of Springer Nature

U2 - 10.1007/s00345-018-2310-y

DO - 10.1007/s00345-018-2310-y

M3 - Article

VL - 36

SP - 1399

EP - 1407

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 9

ER -